Floatz logo

Autologous Cd19/Cd22 Dual-Target Car-T Module

Peripheral T-cell Lymphoma

Beijing BiotechCell therapyPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

135 Active assets in the Peripheral T-cell Lymphoma cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Tarapeutics Science Inc.
Phase 4BBB
Inno-206
BeBetter Med Inc
Phase 4BBB
Pralatrexate
Peking University People's Hospital
Phase 4BBB
Cyclophosphamide
Tarapeutics Science Inc.
Phase 4BBB
(+)-VINCRISTINE
BeBetter Med Inc
Phase 4BBB

View all 50 →

Same molecule, other indications

Autologous Cd19/Cd22 Dual-Target Car-T Module is also rated in:

B-cell acute lymphoblastic leukemiaDormant
CC
Indicative ·
47 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →